WEST COLUMBIA, S.C., June 14, 2016 /PRNewswire/ -- Nephron Pharmaceuticals Corporation (Nephron) launched generic Budesonide Inhalation Suspension yesterday. Nephron has licensed the Abbreviated New Drug Application from Apotex, Inc. Budesonide Inhalation Suspension is the generic version of Pulmicort Respules® manufactured by AstraZeneca LP. Nephron will be responsible for the manufacturing, marketing and distribution of Budesonide.
Budesonide Inhalation Suspension is a widely used, inhaled corticosteroid indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Budesonide Inhalation Suspension is a prescription medication that reduces swelling and inflammation in the lungs, and helps keep the airways open to reduce asthma symptoms. It is dispensed in hospitals, clinics, physicians' offices and pharmacies. See full prescribing information at www.nlm.nih.gov/medlineplus/druginfo/meds/a699056.html for additional information.
Nephron will market two strengths of Budesonide. Both 0.5mg/2mL and 0.25mg/2mL dosage forms will be available in unit-dose vials. The medications are packaged in bulk five-card configurations, as well as individually wrapped and bar-coded singles packaging. Nephron led the market in the development and release of individually wrapped and bar-coded medication in 2001, prior to the 2004 mandate by the Food and Drug Administration.
"Nephron is delighted to enhance our generic respiratory portfolio with the launch of Budesonide Inhalation Suspension. This new product approval is another milestone signaling growth for the company, which further complements our recent expansion into a fully automated state of the art manufacturing facility in West Columbia, South Carolina," said Lou Kennedy, Owner and CEO of Nephron Pharmaceuticals Corporation.
Nephron Pharmaceuticals Corporation is a global leader in manufacturing generic respiratory medications utilizing blow-fill-seal technology. Nephron products are proudly made in the USA! All products are available individually wrapped and bar-coded, and Nephron is the only manufacturer of Racemic Epinephrine. For more information, please visit www.nephronpharm.com.
Apotex is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 10,000 employees and estimated sales of approximately $2 billion.
SOURCE Nephron Pharmaceuticals Corporation